Evaluation of Magnesium Supplementation and Trends in the Incidence of Acute Kidney Injury in Cisplatin-Treated Patients in Our Institution's Database and Real-World Data

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1040240188

Enrollment

Unknown

Registered

2025-02-13

Start date

2025-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older who received cisplatin treatment at Hamamatsu University School of Medicine Hospital from 2008 to October 2024. Patients aged 18 years or older who received cisplatin treatment and are registered in the MDV database (with registrations up to August 2024 as of November 1, 2024).

Exclusion criteria

Exclusion criteria: If the research subject or their representative refuses or withdraws consent for the use of samples or information in this study. Patients with a baseline eGFR of <15 ml/min before cisplatin administration.

Design outcomes

Primary

Measure	Time frame
The proportion of intravenous magnesium supplementation on the first day of cisplatin administration in cisplatin-treated patients.	—

Secondary

Measure	Time frame
Changes in the Proportion of Magnesium Supplementation: By comparing the current and past proportions of magnesium supplementation and analyzing trends over time, this study investigates the extent to which the publication of guidelines has influenced the increase in magnesium supplementation. Changes in the Incidence of Acute Kidney Injury Associated with Magnesium Supplementation: This study examines the incidence of acute kidney injury (AKI) based on KDIGO clinical guidelines (Stage 1: an increase in serum creatinine >0.3 mg/dL or 1.5-2 times the baseline creatinine level; Stage 2: an increase in serum creatinine of more than twice the baseline level). Additionally, the study evaluates the longitudinal changes in the mean and median decline in eGFR from baseline before cisplatin administration and investigates the correlation with the proportion of magnesium supplementation. Proportion of Serum Magnesium Level Measurements: This study also examines the annual trend in the proportion of patients whose serum magnesium levels were measured on the day of cisplatin administration.	—

Measure

Time frame

Changes in the Proportion of Magnesium Supplementation: By comparing the current and past proportions of magnesium supplementation and analyzing trends over time, this study investigates the extent to which the publication of guidelines has influenced the increase in magnesium supplementation. Changes in the Incidence of Acute Kidney Injury Associated with Magnesium Supplementation: This study examines the incidence of acute kidney injury (AKI) based on KDIGO clinical guidelines (Stage 1: an increase in serum creatinine >0.3 mg/dL or 1.5-2 times the baseline creatinine level; Stage 2: an increase in serum creatinine of more than twice the baseline level). Additionally, the study evaluates the longitudinal changes in the mean and median decline in eGFR from baseline before cisplatin administration and investigates the correlation with the proportion of magnesium supplementation. Proportion of Serum Magnesium Level Measurements: This study also examines the annual trend in the proportion of patients whose serum magnesium levels were measured on the day of cisplatin administration.

—

Contacts

Public ContactNaoko Katahashi

Hamamatsu university hospital

kths@hama-med.ac.jp+81-53-435-2111

Outcome results